Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:

Immunovia Interim report, January-March 2018

April 27, 2018

“In the first quarter we reached a very important milestone for the company. Almost two years after the listing of Immunovia on Nasdaq First North, we received approval from Nasdaq to begin trading on their main market.

We have also worked intensively towards our next milestone, which is to start sales by the end of 2018.

The company has a target of achieving turnover of SEK 250-300 million by 2021 … and total turnover of SEK 800-1,000 by 2023.”

Extract from comments to the interim report by CEO Mats Grahn.

Key Indicators

Key Indicators
(SEK 000 unless otherwise stated)
1 Jan-31 March 2018 1 Jan-31 March 2017 Full year 2017 Full year 2016
Net sales 112 28 149 177
Operating earnings -17,377 -7,870 -45,520 -14,978
Earnings before tax -17,326 -7,771 -45,232 -14,723
Net earnings -17,326 -7,771 -45,232 -14,723
Earnings per share before dilution (SEK/share) -1.00 -0.46 -2.67 -0,98
Equity ratio, % 94 97 94 98
No. of shares at the end of the period 17,318,059  16,804,059 17,318,059  16,804,059

This financial statement has been produced in accordance with IFRS for the Immunovia Group, which comprises Immunovia AB and the wholly-owned subsidiaries Immunovia Inc. and Immunovia GmbH.

Immunovia is focused on fundamentally transforming diagnosis of complex forms of cancer and autoimmune diseases. The antibody-based platform, IMMray™, is the result of 15 years of research at CREATE Health – the Center for Translational Cancer Research at Lund University, Sweden. IMMray™ is a technology platform for the development of diagnostic tests and the company’s primary test. IMMray™ PanCan-d is the first test in the world for early diagnosis of pancreatic cancer.

The company expects to receive the first revenues from self-pay sales in Q4 2018.

The following financial targets have been established:

Immunovia’s target is to achieve turnover of SEK 250-300 million by 2021 based on self-pay for IMMray™ PanCan-d.

Immunovia’s target is to achieve total turnover, including payment via self-pay and cost reimbursement from insurance systems, of SEK 800-1,000 million by 2023.

This information is information that Immunovia AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on 27 April at CET 08:00, through the agency of the contact person set out above.  

For further information, please contact:
Mats Grahn, CEO, Immunovia AB
Phone: +46 (0) 70-532 02 30

About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer.  In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source:

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit 


Immunovia Q1 2018 ENG